All In Biotech

Drug Trial Radar · NCT02988960

A Study of ABBV-927 and ABBV-181, an Immunotherapy, in Participants With Advanced Solid Tumors

A Multicenter, Phase 1, Open-Label, Dose-Escalation Study of ABBV-927 and ABBV-181, an Immunotherapy, in Subjects With Advanced Solid Tumors

Last checked: Nov 20, 2026Latest source record: Jan 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

163

Actual

Start

Feb 22, 2017

Primary completion

Sep 2026

Study completion Sep 2026

Sponsor

Lead sponsor
AbbVieAbbVie (ABBV)
Sponsor type
Industry
First posted
Dec 12, 2016

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a dose-escalation study designed to evaluate the safety, pharmacokinetics, and pharmacodynamics of ABBV-927, and to determine the maximum tolerated dose (MTD) or recommended Phase 2 dose (RPTD) for ABBV-927 when administered as monotherapy or as combination therapy with ABBV-181 in participants with advanced solid tumors.

Conditions

  • Advanced Solid Tumors Cancer

Interventions

  • ABBV-927Drug

    Intravenous

  • ABBV-927Drug

    Intratumoral

  • ABBV-181Drug

    Intravenous

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Maximum tolerated dose (MTD) or recommended Phase 2 dose (RPTD) for ABBV-927 when administered as monotherapy or as combination therapy with ABBV-181Time frame: Up to 8 weeks
  2. Time to Cmax (Tmax) of ABBV-927Time frame: Up to 12 weeks after participant's first dose
  3. Maximum observed serum concentration (Cmax) of ABBV-927Time frame: Up to 12 weeks after participant's first dose
  4. Terminal-Phase Elimination Rate Constant (β) of ABBV-927Time frame: Up to 12 weeks after participant's first dose
  5. Terminal half-life (t1/2) of ABBV-927Time frame: Up to 4 weeks after participant's first dose
  6. Area under the serum concentration-time curve (AUCt) of ABBV-927Time frame: Up to 12 weeks after participant's first dose
  7. Time to Cmax (Tmax) of ABBV-181Time frame: Up to 12 weeks after participant's first dose
  8. Maximum observed serum concentration (Cmax) of ABBV-181Time frame: Up to 12 weeks after participant's first dose
  9. Terminal-Phase Elimination Rate Constant (β) of ABBV-181Time frame: Up to 12 weeks after participant's first dose
  10. Terminal half-life (t1/2) of ABBV-181Time frame: Up to 4 weeks after participant's first dose
  11. Area under the serum concentration-time curve (AUCt) of ABBV-181Time frame: Up to 12 weeks after participant's first dose
  12. Number of Participants with Adverse EventsTime frame: Up to 30 days after and up to 24-month of treatment period

Locations

22 sites in 7 countries. Site status is shown where the registry gives one.

  • The Angeles Clinic and Researc /ID# 156324

    Los Angeles, California

  • The University of Chicago Medical Center /ID# 155264

    Chicago, Illinois

  • Massachusetts General Hospital /ID# 155267

    Boston, Massachusetts

  • Carolina BioOncology Institute /ID# 155265

    Huntersville, North Carolina

  • Tennessee Oncology-Nashville Centennial /ID# 158654

    Nashville, Tennessee

  • University of Texas MD Anderson Cancer Center /ID# 155263

    Houston, Texas

  • Virginia Cancer Specialists - Fairfax /ID# 155266

    Fairfax, Virginia

  • Peninsula Oncology Centre /ID# 164372

    Frankston, Victoria, Australia

  • Austin Health /ID# 171189

    Heidelberg, Victoria, Australia

  • University Health Network_Princess Margaret Cancer Centre /ID# 200819

    Toronto, Ontario, Canada

  • Institut Bergonie /ID# 162665

    Bordeaux, Gironde, France

  • Duplicate_Institut Regional du Cancer /ID# 163609

    Montpellier, Herault, France

  • Centre Leon Berard /ID# 162663

    Lyon, Rhone, France

  • Institut Gustave Roussy /ID# 162666

    Villejuif, Val-de-Marne, France

  • National Cancer Center Hospital East /ID# 216870

    Kashiwa-shi, Chiba, Japan

  • National Cancer Center Hospital /ID# 217758

    Chuo-ku, Tokyo, Japan

  • Yonsei University Health System Severance Hospital /ID# 166292

    Seoul, South Korea

  • Seoul National University Hospital /ID# 166291

    Seoul, Seoul Teugbyeolsi, South Korea

  • Hospital Universitario Fundacion Jimenez Diaz /ID# 200128

    Madrid, Spain

  • Hospital Universitario HM Sanchinarro /ID# 200127

    Madrid, Spain

  • Hospital Universitario y Politecnico La Fe /ID# 200975

    Valencia, Spain

  • Hospital Universitario Puerta de Hierro - Majadahonda /ID# 200129

    Majadahonda, Madrid, Spain

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.